Proteotype Diagnostics said it is initiating a new clinical study for Enlighten, its multicancer early detection test, to support a CE-IVDR submission, as it accelerates toward commercialization. The Cambridge, UK-based company also plans a parallel study intended to optimize its platform and technology performance. CEO Wesley Sukdao said the company is preparing to raise about £5 million (~$6.8 million) and is hiring to expand internal regulatory and product development capacity. Proteotype’s reported Enlighten workflow uses a qualitative in vitro blood test analyzing cross-sectional patterns across select amino-acid residue biomarkers and machine-learning software. The company pointed to prior biomarker validation work in 170 participants, including a reported 78% cancer identification rate without misclassifying healthy controls, plus the ability to distinguish cancer from autoimmune or infectious disease signals. The new studies will be watched for regulatory readiness and evidence durability under conformity and performance requirements.